Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. .; (Microbial infection) May serve as a receptor for adhesin A variant 3 (nadA) of N.meningitidis. .

P78380

Oxidized low-density lipoprotein receptor 1 (Ox-LDL receptor 1) (C-type lectin domain family 8 member A) (Lectin-like oxidized LDL receptor 1) (LOX-1) (Lectin-like oxLDL receptor 1) (hLOX-1) (Lectin-type oxidized LDL receptor 1) [Cleaved into: Oxidized low-density lipoprotein receptor 1, soluble form],OLR1 CLEC8A LOX1,C-type lectin domain family 8 member A, LOX-1, Ox-LDL receptor 1, Lectin-like oxidized LDL receptor 1, OLR1, Oxidized low-density lipoprotein receptor 1, Lectin-like oxLDL receptor 1, LOX1, CLEC8A, hLOX-1, Lectin-type oxidized LDL receptor 1

Human

FC

FC 1:50-1:200

31kD

PerCP

Mouse

Monoclonal

SA1024

IgG2a

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

0.5 mg/ml

Store at 4℃ for 12 months. Protect from light. Do not freeze.